Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: Selumetinib in patients with cholangiocarcinoma

British Journal of Cancer

Volumn 106, Issue 10, 2012, Pages 1583-1586

  Prado, C M M ^a   Bekaii Saab, T ^b   Doyle, L A ^c   Shrestha, S ^a   Ghosh, S ^a   Baracos, V E ^a   Sawyer, M B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cachexia; Cholangiocarcinoma; Interleukin 6; Skeletal muscle

Indexed keywords

CAPECITABINE; CARBOPLATIN; ETOPOSIDE; GEMCITABINE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; SELUMETINIB;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BODY COMPOSITION; CACHEXIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; MALE; MUSCLE DEVELOPMENT; MUSCLE MASS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIDE EFFECT; SKELETAL MUSCLE;

ADULT; AGED; BENZIMIDAZOLES; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CACHEXIA; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUSCLE, SKELETAL; PROTEIN KINASE INHIBITORS;

EID: 84860739691     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.144     Document Type: Article

References (32)

1. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE (2010) Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebocontrolled study. J Clin Oncol 28: 1054-1060
2. Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ (2009) The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 3: 263-268
3. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S (2010) Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 91: 1133S-1137S
4. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA (2011) Multiinstitutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29: 2357-2363
5. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3: 1014-1019 (Pubitemid 34428747)
6. Bruce CR, Dyck DJ (2004) Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 287: E616-E621 (Pubitemid 39237888)
7. Cooperman AM, Chivati J, Chamberlain RS (2000) Nutritional and metabolic aspects of pancreatic cancer. Curr Opin Clin Nutr Metab Care 3: 17-21 (Pubitemid 30469100)
8. Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, Steiner MS (2011) Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 62: 265-279
9. Durham WJ, Dillon EL, Sheffield-Moore M (2009) Inflammatory burden and amino acid metabolism in cancer cachexia. Curr Opin Clin Nutr Metab Care 12: 72-77
10. Edinger AL, Thompson CB (2002) Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13: 2276-2288 (Pubitemid 34831333)
11. Eli Lilly and Company (2012) A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US): Bethesda (MD),-[cited 27 Feb 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01505530. NML identifier: NCT01505530
12. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, Macdonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12: 489-495
13. Frontera WR, Meredith CN, O'Reilly KP, Knuttgen HG, Evans WJ (1988) Strength conditioning in older men: skeletal muscle hypertrophy and improved function. J Appl Physiol 64: 1038-1044 (Pubitemid 18088522)
14. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE (1998) Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 227: 398-404 (Pubitemid 28131021)
15. Jo C, Cho SJ, Jo SA (2011) Mitogen-activated protein kinase kinase 1 (MEK1) stabilizes MyoD through direct phosphorylation at tyrosine 156 during myogenic differentiation. J Biol Chem 286: 18903-18913
16. Lieffers JR, Mourtzakis M, Hall KD, McCargar LJ, Prado CM, Baracos VE (2009) A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 89: 1173-1179
17. MacDonald N, Easson AM, Mazurak VC, Dunn GP, Baracos VE (2003) Understanding and managing cancer cachexia. J Am Coll Surg 197: 143-161 (Pubitemid 36759189)
18. Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V (2009) Cholangiocarcinoma. Crit Rev Oncol Hematol 69: 259-270
19. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33: 997-1006
20. Murphy KT, Lynch GS (2009) Update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 14: 619-632
21. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13: 3264-3268 (Pubitemid 46944911)
22. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15: 2920-2926
23. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9: 629-635
24. Revill P, Serradell J, Bolos J, Bozzo J (2006) AZD-6244. Drugs Fut 31: 854-858
25. Saini A, Al-Shanti N, Stewart CE (2006) Waste management-cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 17: 475-486 (Pubitemid 44793120)
26. Saini A, Faulkner S, Al-Shanti N, Stewart C (2009) Powerful signals for weak muscles. Ageing Res Rev 8: 251-267
27. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, Heymsfield SB, Heshka S (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97: 2333-2338 (Pubitemid 39552474)
28. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC (2007) Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 110: 1656-1663 (Pubitemid 47443984)
29. Zaki MH, Nemeth JA, Trikha M (2004) CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 111: 592-595 (Pubitemid 39045327)
30. Zhang D, Zheng H, Zhou Y, Tang X, Yu B, Li J (2007) Association of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer. BMC Cancer7 45
31. Zhang D, Zhou Y, Wu L, Wang S, Zheng H, Yu B, Li J (2008) Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. Ann Clin Lab Sci 38: 113-119 (Pubitemid 351671392)
32. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ (2010) Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142: 531-543